November 23, 2015
In our most recent paper “Treatment during a vulnerable developmental period rescues a genetic epilepsy” by Stephan Marguet & Quyen Le-Schulte et al., which was published online by Nature Medicine on November 23, 2015 (
doi:10.1038/nm.398), we report that a pharmacological intervention timed during a vulnerable neonatal period of cortical development prevents pathology in a genetic epilepsy model. Using the substance bumetanide in newborn mice with Kv7 encephalopathy, we succeeded in attenuating the disease progression, allowing the animals to develop almost normally (DZNE press release; PDF).